SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 30, 2019
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
11099 N. Torrey Pines Road, Suite 190
La Jolla, California
|(Address of principal executive offices)||(Zip Code)|
Registrants telephone number, including area code: (858) 750-4789
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange on which registered
|Common Stock, par value $0.001 per share||THOR||The Nasdaq Global Select Market|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
|Item 1.01|| |
Entry into a Material Definitive Agreement.
On August 30, 2019, Synthorx, Inc. (the Company) entered into a Sub-Sublease (the Sublease) with Avelas Biosciences, Inc. (Avelas) for office and laboratory space located at 11099 North Torrey Pines Road, California (the Premises). The purpose of the Sublease is to provide the Company with additional office and laboratory space in the same building as the Companys existing principal office is located.
Under the terms of the Sublease, commencing on or around September 1, 2019 (the Commencement Date), the Company will sublease approximately 7,109 square feet in the Premises (the Rented Area) at the rate of $24,858.23 per month (the Base Rate), with no Base Rate payable for the first six months following the Commencement Date. The Base Rate is scheduled to increase to $25,603.97 per month beginning on March 1, 2021, and the Company is also responsible for certain operating expenses throughout the life of the Sublease.
The Sublease will continue until February 29, 2022. The Company has the option to extend the Sublease for one successive one-year term for which the Base Rate would be increased to $26,372.09 per month.
Avelas is affiliated with COI Pharmaceuticals, Inc. (COI). Jay Lichter, Ph.D., a member of the Companys board of directors, and Tighe Reardon, the Companys Acting Chief Financial Officer, are each executive officers and directors of COI, a shared service company that provides certain back-office and administrative and research and development support services, including facilities support, to the portfolio companies of Avalon Ventures, one of the Companys principal stockholders. As disclosed in certain of the Companys other filings with the Securities and Exchange Commission, the Company and COI are parties to a services agreement and the Company subleases office space from COI in the Premises.
The foregoing description of the terms of the Sublease does not purport to be complete, and is qualified in its entirety by reference to the full text of the Sublease, which will be filed with the Companys Quarterly Report on Form 10-Q for the period ending on September 30, 2019
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Dated: September 4, 2019||By:|
|Laura Shawver, Ph.D.|
|President and Chief Executive Officer|